Compare ALNT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | CRVS |
|---|---|---|
| Founded | 1962 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1995 | 2016 |
| Metric | ALNT | CRVS |
|---|---|---|
| Price | $65.96 | $15.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $64.50 | $30.17 |
| AVG Volume (30 Days) | 157.9K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 67.09 | 48.04 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $554,478,000.00 | N/A |
| Revenue This Year | $7.53 | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $206.75 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $29.25 | $3.38 |
| 52 Week High | $80.39 | $26.95 |
| Indicator | ALNT | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 48.51 |
| Support Level | $57.71 | $13.81 |
| Resistance Level | $67.79 | $19.21 |
| Average True Range (ATR) | 3.65 | 1.21 |
| MACD | -1.04 | -0.09 |
| Stochastic Oscillator | 26.29 | 20.30 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty controlled motion components and systems. The firm mainly caters to the Industrial, Vehicle, Aerospace & Defense, and Medical sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.